Why immune activation happens in Alzheimer's-related dementia linked to GBA mutations
Mechanism of innate immune activation in a Drosophila model of Alzheimer's disease related dementia
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11263667
Researchers are learning whether buildup of a fatty sugar called glucosylceramide and changes in tiny cell particles trigger immune reactions that harm brain cells in Alzheimer's-related dementias tied to GBA mutations.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11263667 on ClinicalTrials.gov |
What this research studies
This project uses fruit flies engineered to lack the fly version of the human GBA gene to model glucocerebrosidase deficiency and the resulting buildup of glucosylceramide. The team measures brain protein aggregates, neurodegeneration, and age-related memory decline while using RNA sequencing and RNAi screens to find which innate immune pathways change. Researchers focus on extracellular vesicles and a p38 MAPK transcription factor (Atf-2) to see if altering vesicle production or those pathways reduces inflammation and neuronal damage. Results in flies will identify molecular targets that could guide future studies in human tissues or clinical research.
Who could benefit from this research
Good fit: People with Lewy body dementia or other Alzheimer's-related dementias, especially those with known GBA mutations or a family history, are most relevant to this research.
Not a fit: Because the work is done in fruit flies and is not a treatment trial, people seeking immediate therapies or those without GBA-related risk are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets to reduce neuroinflammation and protect brain cells in people at risk for GBA-related Alzheimer's-type dementias.
How similar studies have performed: Prior laboratory studies in cells and animal models have shown that changing extracellular vesicle production or related immune pathways can reduce pathology, but translating those findings to human treatments has not yet been achieved.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PALLANCK, LEO J — UNIVERSITY OF WASHINGTON
- Study coordinator: PALLANCK, LEO J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.